Search results for " Macro"

showing 10 items of 522 documents

Acquatina Lagoon: a model ecosystem to study community patterns

2013

Acquatina is a small lagoon ecosystem (0.45 km2) located on the Adriatic coast only 5 km north of Lecce (Italy). The lagoon has a freshwater input in the northern part and a connection with the sea at the south edge, being characterised by a latitudinal gradient of salinity and an internal patchiness of habitats. Here, we have used the lagoons as a model to study the influence of these sources of variation on the spatial distribution of macrobenthis and fish fauna, using both taxonomic and on taxonomic descriptors. Results showed a non random distribution of both species and functional traits of macroinvertebrate and fish fauna within the lagoon, despite the relatively small surface area. S…

Acquatina Lagoon habitat patchiness gradient of salinity functional traits macroinvertebrates fish fauna niche specialisation trophic energy partitioninglagoon macroinvertebrate fishspatial distribution
researchProduct

Characterization of Intertidal Macrofaunal Communities of Two Sandy Beaches under Different Anthropogenic Pressures

2022

The macrofauna in the intertidal zone of sandy beaches provides the trophic connectivity between land and sea, by linking microbiome, meiofauna, and megafauna, representing a food source for several terrestrial animals, including shorebirds and mammals. However, the macrozoobenthos in urbanised beaches is subjected to intense disturbances, such as breakwater barriers and tourism, which limit or impede the energy transfer from the marine to the terrestrial habitats. Because the information about diversity and abundance of the macrozoobenthos of the intertidal zone on the Mediterranean sandy coasts is scant, the main objective of this study is to increase the knowledge on the macrofauna livin…

Adriatic SeaAdriatic Sea; macrozoobenthos; biodiversity; artificial barriers; marine protected areasSettore BIO/05 - ZoologiaOcean Engineeringartificial barriermacrozoobenthobiodiversitymarine protected areasWater Science and TechnologyCivil and Structural EngineeringJournal of Marine Science and Engineering; Volume 10; Issue 12; Pages: 1976
researchProduct

Subclinical Mastitis in a European Multicenter Cohort: Prevalence, Impact on Human Milk (HM) Composition, and Association with Infant HM Intake and G…

2019

Background: Subclinical mastitis (SCM) is an inflammatory condition of the mammary gland. We examined the effects of SCM on human milk (HM) composition, infant growth, and HM intake in a mother&ndash

Adult0301 basic medicineLongitudinal study[SDV]Life Sciences [q-bio]Mammary glandPhysiologylcsh:TX341-641MastitisArticleCohort Studies03 medical and health sciences0302 clinical medicinemedicineHumansSubclinical mastitissubclinical mastitisMinerals030219 obstetrics & reproductive medicine030109 nutrition & dieteticsNutrition and DieteticsMilk Humanbusiness.industryfungiInfant Newbornlongitudinal studyInfanthuman milkFeeding BehaviorEuropean populationmedicine.diseaseTrace Elements3. Good healthMastitisEuropeNäringsläraBreast Feedingmedicine.anatomical_structureCohortmilk macronutrientsFemaleEuropean populationbusinesslcsh:Nutrition. Foods and food supplyEuropean population; human milk; longitudinal study; milk macronutrients; subclinical mastitisFood ScienceNutrients
researchProduct

Modulation of adipokines and cytokines in gestational diabetes and macrosomia.

2006

Abstract Context/Objective: Not much is known about the implication of adipokines and different cytokines in gestational diabetes mellitus (GDM) and macrosomia. The purpose of this study was to assess the profile of these hormones and cytokines in macrosomic babies, born to gestational diabetic women. Design/Subjects: A total of 59 women (age, 19–42 yr) suffering from GDM with their macrosomic babies (4.35 ± 0.06 kg) and 60 healthy age-matched pregnant women and their newborns (3.22 ± 0.08 kg) were selected. Methods: Serum adipokines (adiponectin and leptin) were quantified using an obesity-related multiple ELISA microarray kit. The concentrations of serum cytokines were determined by ELISA…

AdultBlood GlucoseLeptinMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismClinical BiochemistryAdipokineBiochemistryProinflammatory cytokineFetal MacrosomiaInterferon-gammaEndocrinologyAldesleukinPregnancyInternal medicineDiabetes mellitusFetal macrosomiaMedicineHumansInsulinAdiponectinbusiness.industryInterleukin-6Tumor Necrosis Factor-alphaLeptinBiochemistry (medical)Infant Newbornmedicine.diseaseLipidsGestational diabetesDiabetes GestationalEndocrinologyCytokinesInterleukin-2FemaleAdiponectinInterleukin-4businessThe Journal of clinical endocrinology and metabolism
researchProduct

Implication of lipids in macrosomia of diabetic pregnancy: can n-3 polyunsaturated fatty acids exert beneficial effects?

2003

Macrosomia or fetal obesity is a frequent complication of pregnancy in diabetes mellitus. Several alterations observed in carbohydrate and lipid metabolism in macrosomic infants of diabetic mothers are thought to be a consequence of maternal hyperglycaemia leading to fetal hyperinsulinaemia. Macrosomic infants of diabetic mothers are prone to the development of glucose intolerance, obesity and diabetes during childhood and adulthood. Furthermore, increasing evidence is accumulating regarding the importance of n-3 polyunsaturated fatty acids (PUFAs) in the reduction of plasma lipids and hyperglycaemia. In this review article, we shed light on the abnormalities in lipid metabolism in macrosom…

AdultBlood GlucoseMalemedicine.medical_specialtyendocrine system diseasesLipoproteinsPregnancy in DiabeticsFetal MacrosomiaPregnancyDiabetes mellitusInternal medicineFatty Acids Omega-3Diabetes MellitusmedicineAnimalsHumansObesitychemistry.chemical_classificationPregnancyFetusbusiness.industryMetabolic disorderInfant NewbornLipid metabolismGeneral MedicineLipid Metabolismmedicine.diseaseObesityGestational diabetesEndocrinologychemistryFemaleInsulin ResistancebusinessPolyunsaturated fatty acidClinical Science
researchProduct

Pharmacotherapy for gestational diabetes mellitus: still insulin, or what about sulfonylureas?

2018

Randomized trials have not focused on neonatal complications of glyburide for women with gestational diabetes.To compare oral glyburide vs subcutaneous insulin in prevention of perinatal complications in newborns of women with gestational diabetes.The Insulin Daonil trial (INDAO), a multicenter noninferiority randomized trial conducted between May 2012 and November 2016 (end of participant follow-up) in 13 tertiary care university hospitals in France including 914 women with singleton pregnancies and gestational diabetes diagnosed between 24 and 34 weeks of gestation.Women who required pharmacologic treatment after 10 days of dietary intervention were randomly assigned to receive glyburide …

AdultBlood Glucosemedicine.medical_specialtyendocrine system diseasesInjections Subcutaneousmedicine.medical_treatmentAdministration Oral030209 endocrinology & metabolism.OverweightInfant Newborn DiseasesFetal Macrosomia03 medical and health sciences0302 clinical medicinePharmacotherapyInsulin resistancePregnancyInternal medicineGlyburidemedicineHumansHypoglycemic AgentsInsulin030212 general & internal medicineFamily historyHyperbilirubinemiabusiness.industryInsulinInfant NewbornPregnancy Outcomenutritional and metabolic diseasesType 2 Diabetes MellitusGeneral Medicinemedicine.diseaseHypoglycemiafemale genital diseases and pregnancy complicationsGestational diabetesDiabetes GestationalEditorialEndocrinologyFemalemedicine.symptomMetabolic syndromebusinessAnnals of Translational Medicine
researchProduct

The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients…

2008

Lymphoplasmacytic lymphoma (LPL) is an indolent lymphoma with moderate sensitivity to conventional chemotherapy. This study investigated whether the addition of rituximab to standard chemotherapy improves treatment outcome in LPL and the subgroup of LPL patients fulfilling the criteria of Waldenstroem's macroglobulinemia (WM). A total of 69 patients with previously untreated LPL were enrolled into the trial; 64 patients were evaluable for treatment outcome. In all, 48 of the 64 LPL patients fulfilled the criteria of WM. Patients were randomly assigned to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, n=34) or CHOP (n=30). R-CHOP resulted in significantly highe…

AdultCancer Researchmedicine.medical_specialtyVincristineCyclophosphamidemedicine.medical_treatmentCHOPGastroenterologyDisease-Free SurvivalLymphoplasmacytic LymphomaAntibodies Monoclonal Murine-Derived03 medical and health sciences0302 clinical medicineimmune system diseasesPrednisonehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCyclophosphamideAgedChemotherapybusiness.industryRemission InductionAntibodies MonoclonalHematologyMiddle Agedmedicine.disease3. Good healthLymphomaSurgeryTreatment OutcomeOncologyDoxorubicinVincristine030220 oncology & carcinogenesisPrednisoneRituximabWaldenstrom MacroglobulinemiaRituximabbusiness030215 immunologymedicine.drugLeukemia
researchProduct

Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection

2019

Background and aims Chronic hepatitis C virus (HCV) infection increases the risk of incident chronic kidney disease (CKD) and progression to end-stage renal disease (ESRD). Previously available direct-acting antiviral regimens are not approved for patients with advanced CKD across all HCV genotypes. Methods EXPEDITION-5 is a phase 3 study to evaluate efficacy and safety of the fixed-dose combination of glecaprevir and pibrentasvir (G/P) for chronic HCV infection (genotype 1 through 6) in adults without cirrhosis or with compensated cirrhosis and with stage 3b, 4 or 5 CKD. Patients received approved duration of G/P according to HCV genotype, cirrhosis status and prior HCV treatment experienc…

AdultCyclopropaneshepatitis C virusmedicine.medical_specialtyAminoisobutyric AcidsPyrrolidinesCirrhosisProlineLactams Macrocyclicmedicine.medical_treatmentAntiviral Agents03 medical and health sciences0302 clinical medicineLeucineQuinoxalinesInternal medicineGenotypeHumansMedicineAdverse effectDialysisSulfonamidesdirect-acting antiviralpangenotypicHepatologychronic kidney disease; cirrhosis; direct-acting antiviral; hepatitis C virus; pangenotypicbusiness.industrycirrhosisGlecaprevirHepatitis C Chronicmedicine.diseasePibrentasvirDrug Combinations030220 oncology & carcinogenesisBronchitisBenzimidazoles030211 gastroenterology & hepatologybusinesschronic kidney diseaseKidney disease
researchProduct

A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in pati…

1993

After informed consent, 86 patients with advanced cancer undergoing potentially myelosuppressive cytotoxic chemotherapy were randomized to receive placebo or subcutaneous granulocyte - colony stimulating factor (G- CSF) 5 μg/Kg/day in order to prevent severe neutropenia and its related morbidity. The incidence of neutropenia (absolute neutrophil count <1, 000/mm3) was significantly reduced in patients receiving G-CSF than in controls (18% versus 42%; P <0.05). The duration of neutropenia was also shortened by the administration of G-CSF (4.8 versus 8.2 days; P <0.05). Therapy with G-CSF has also a positive impact on the dose-intensity of employed regimens. Patients treated with G-CSF showed…

AdultMale0301 basic medicineMicrobiology (medical)medicine.medical_specialtyNeutropeniaTime FactorsFeverInjections Subcutaneousmedicine.medical_treatment030106 microbiologyAntineoplastic AgentsNeutropeniaGranulocytePlaceboGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineGranulocyte Colony-Stimulating FactormedicineHumansPharmacology (medical)Prospective StudiesNeoplasm MetastasisAgedPharmacologyChemotherapybusiness.industryIncidenceIncidence (epidemiology)CarcinomaMiddle Agedmedicine.diseaseRecombinant ProteinsGranulocyte colony-stimulating factorSurgeryInfectious DiseasesGranulocyte macrophage colony-stimulating factormedicine.anatomical_structureOncology030220 oncology & carcinogenesisAbsolute neutrophil countFemalebusinessmedicine.drug
researchProduct

Clinical and neuroimaging findings in 33 patients with MCAP syndrome: A survey to evaluate relevant endpoints for future clinical trials

2021

Megalencephaly-CApillary malformation-Polymicrogyria (MCAP) syndrome results from somatic mosaic gain-of-function variants in PIK3CA. Main features are macrocephaly, somatic overgrowth, cutaneous vascular malformations, connective tissue dysplasia, neurodevelopmental delay, and brain anomalies. The objectives of this study were to describe the clinical and radiological features of MCAP, to suggest relevant clinical endpoints applicable in future trials of targeted drug therapy. Based on a French collaboration, we collected clinical features of 33 patients (21 females, 12 males, median age of 9.9 years) with MCAP carrying mosaic PIK3CA pathogenic variants. MRI images were reviewed for 21 pat…

AdultMale0301 basic medicinePediatricsmedicine.medical_specialtyCutis marmorataAdolescentClass I Phosphatidylinositol 3-KinasesNeuroimagingContext (language use)Skin Diseases Vascular030105 genetics & heredityCohort StudiesYoung Adult03 medical and health sciencesGeneticsPolymicrogyriamedicineHumansPROSAbnormalities MultipleTelangiectasisMegalencephalyChildMCAP syndromeGenetics (clinical)Chiari malformationClinical Trials as Topicbusiness.industryMacrocephalyPIK3CAmedicine.diseaseMagnetic Resonance ImagingMegalencephaly3. Good healthClinical trial030104 developmental biologyChild PreschoolPostnatal macrocephalyFemalemedicine.symptombusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyForecastingVentriculomegalyClinical Genetics
researchProduct